Eli Lilly and Company (NYSE:LLY) revealed on Tuesday that it will supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in patients aged 12 years and older who do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19, under a Joint Procurement Agreement with the European Commission (EC).

This agreement will provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from the company and follows the scientific opinion under Article 5(3) of Regulation 726/2004 issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).

The company added that the preclinical data from its labs have demonstrated that bamlanivimab and etesevimab administered together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha.

Based on the high transmissibility of the Delta variant, currently over 95% of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant, stated the company.

According to the company, bamlanivimab administered with etesevimab is available under emergency pathways in 15 countries around the world for the treatment of COVID-19.